ClinConnect ClinConnect Logo
Search / Trial NCT02482558

Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects

Launched by UNILEVER R&D · Jun 23, 2015

Trial Information

Current as of May 30, 2025

Completed

Keywords

Glycaemic Index Nafld Glycogen Liver Diet

ClinConnect Summary

8 Healthy subject will be scanned the start and end of a 7 day high versus low glycaemic in diet with a 4 week washout between arms. During scan days the hepatic glycogen response to a corresponding high versus low glycaemic index test meal will be measured using 13C Magnetic resonance spectroscopy (MRS) to explore any acute changes in metabolic response. Baseline liver lipid levels will be measured using 1H MRS to explore any long term changes in liver lipid levels.

Blood samples will also be obtained throughout the test day to measure for blood glucose, insulin and blood hormone response...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Male
  • Caucasian
  • Self-reported non-athletic but healthy: not carrying out strenuous exercise (no high sweat, out of breath, high heart rate activities and less than 2 hours moderate exercise a week), moderate drinkers (less than 3 units a day), no smokers
  • Routinely eating 3 meals a day
  • Stable weight
  • Age ≥ 18 and ≤ 35
  • Body mass index (BMI - weight / squared height ) ≥ 20.0 and ≤ 27.0 kg/m2
  • Suitable for MRI scanning (e.g., absence of metal implants, infusion pumps and pacemakers) as assessed by the attached MRI safety questionnaire.
  • Suitable for blood samples and cannula insertion (e.g., no aversion to needles)
  • Willing to follow both prescribed diet plans
  • Not taking any concurrent medication
  • Exclusion Criteria:
  • No diabetics or other metabolic disorders (e.g. insulin resistance, thyroid dysfunction)
  • No volunteers with liver disease
  • No clotting disorders
  • No Participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.
  • No use of any medically or self-prescribed diet from the moment of pre-study examination till the end of the study
  • Taking prescription medication or any other drugs that may influence liver function or glucose and energy metabolism.
  • Any allergy or food intolerance
  • Unsuitable for MR scanning (i.e. have pacemakers and/or medical implants)
  • The subject is an employee of Unilever or the site conducting the study.

About Unilever R&D

Unilever R&D is a leading global research and development organization dedicated to advancing science and innovation in consumer goods, particularly in the areas of personal care, home care, and food products. With a commitment to sustainability and health, Unilever R&D employs cutting-edge research methodologies and collaborates with academic institutions, industry partners, and regulatory bodies to drive product innovation and improve consumer well-being. Their clinical trials focus on evaluating the efficacy and safety of new formulations, ensuring that Unilever consistently delivers high-quality, scientifically validated products that meet the evolving needs of consumers worldwide.

Locations

Nottingham, Nottinghamshire, United Kingdom

Patients applied

0 patients applied

Trial Officials

Penny Gowland, PhD

Principal Investigator

School of Physics & Astronomy, University of Nottingham

Robin Spiller, MD

Principal Investigator

School of Medicine, University of Nottingham

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials